arterioscope is a tech spin-off from Graz University of Technology developing an AI-powered ECG intelligence and digital biomarker platform for cardiovascular drug development.

Our platform enables biotech and pharmaceutical companies to extract early mechanistic signal from routine 12-lead ECG data - transforming high-variance cardiac endpoints into structured, cohort-level intelligence across Phase I–III trials.

By reducing interpretability risk in small, heterogeneous populations, arterioscope supports:

- Earlier signal detection in Phase I/II
- Improved responder / non-responder stratification
- Smarter enrichment strategies
- Reduced variance and capital-efficient Phase IIb/III design

Starting with advanced ECG-based digital biomarkers, our modular platform is expanding into a scalable intelligence layer for cardiovascular R&D - designed to strengthen go/no-go decisions before large-scale capital deployment.

We are building the ECG intelligence infrastructure for next-generation cardiovascular drug development.

👉 Partner with us to bring cardiovascular therapies to patients faster and more efficiently.

arterioscope

Org chart

Teams

Offices